IART INTEGRA LIFESCIENCES HOLDINGS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 917520 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.8%
TTM net income YoY102.6%
TTM EPS YoY102.6%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-49.5%
Margins
Gross margin52.4%
Operating margin4.4%
Net margin0.8%
FCF margin5.2%
EBITDA margin—
Returns
ROE1.2%
ROA0.4%
ROIC (approx.)2.8%
Asset turnover0.46x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity0.65x
Current ratio3.62x
Interest coverage0.79x
Cash quality & payout
Operating cash flow / net income10.79x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $411.18M | $418.76M | $391.92M | $434.93M | $402.06M | $415.61M | $382.65M | $442.65M |
| Cost of revenue | $201.32M | $199.02M | $174.94M | $214.06M | $195.07M | $206.27M | $188.22M | $193.57M |
| Gross profit | $209.87M | $219.74M | $216.98M | $220.87M | $206.99M | $209.33M | $194.43M | $249.07M |
| R&D expense | $21.90M | $24.25M | $23.50M | $24.79M | $22.46M | $27.00M | $24.73M | $31.21M |
| SG&A expense | $165.31M | $172.44M | $178.24M | $169.27M | $169.05M | $179.89M | $181.50M | $178.52M |
| Operating income | $18.90M | $19.29M | $11.47M | $23.04M | $11.76M | -$512.67M | -$15.50M | $35.63M |
| Interest expense | $22.96M | $22.99M | $22.46M | $23.67M | $22.73M | $21.04M | $18.82M | $18.98M |
| Pretax income | $15.66M | $4.74M | -$2.41M | $4.31M | -$6.82M | -$530.95M | -$30.04M | $22.54M |
| Income tax | $812,000 | $262,000 | $2.21M | $6.01M | -$1.42M | -$46.88M | -$4.74M | $3.11M |
| Net income | $14.85M | $4.48M | -$4.62M | -$1.70M | -$5.40M | -$484.07M | -$25.29M | $19.43M |
| EPS (basic) | 0.19 | 0.06 | -0.06 | — | -0.07 | -6.31 | -0.33 | — |
| EPS (diluted) | 0.19 | 0.06 | -0.06 | — | -0.07 | -6.31 | -0.33 | — |
| Weighted avg. shares (diluted) | 78.58M | 78.17M | 76.95M | — | 76.75M | 76.69M | 76.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $252.26M | $214.41M | $236.81M | $235.05M | $232.19M | $217.91M | $239.10M | $246.38M |
| Short-term investments | $59.67M | $59.67M | $28.69M | $28.69M | $35.69M | $35.69M | $34.19M | $27.19M |
| Receivables | $248.99M | $267.19M | $264.41M | $278.85M | $262.16M | $284.51M | $252.45M | $272.37M |
| Inventory | $464.45M | $492.00M | $495.04M | $492.74M | $489.11M | $465.13M | $445.42M | $429.09M |
| Current assets | $1.19B | $1.19B | $1.17B | $1.16B | $1.14B | $1.14B | $1.11B | $1.08B |
| PP&E, net | $441.14M | $446.20M | $446.88M | $444.33M | $437.37M | $434.82M | $422.91M | $405.72M |
| Goodwill | $607.83M | $611.14M | $613.25M | $615.16M | $615.20M | $616.43M | $1.11B | $1.10B |
| Intangibles | $1.04B | $1.08B | $1.11B | $1.13B | $1.16B | $1.19B | $1.19B | $1.21B |
| Total assets | $3.51B | $3.56B | $3.58B | $3.60B | $3.65B | $3.67B | $4.05B | $4.04B |
| Current liabilities | $329.00M | $330.88M | $346.85M | $455.98M | $364.05M | $929.81M | $918.45M | $922.13M |
| Long-term debt | $697.50M | $707.19M | $716.88M | $726.56M | $736.25M | $745.94M | $755.62M | $760.47M |
| Total debt | $697.50M | $707.19M | $716.88M | $726.56M | $736.25M | $745.94M | $755.62M | $760.47M |
| Total liabilities | $2.44B | $2.52B | $2.54B | $2.56B | $2.61B | $2.63B | $2.53B | $2.49B |
| Shareholders' equity | $1.07B | $1.04B | $1.04B | $1.04B | $1.04B | $1.04B | $1.52B | $1.55B |
| Net debt | $445.24M | $492.77M | $480.07M | $491.51M | $504.06M | $528.02M | $516.52M | $514.09M |
| Cash flow statement | ||||||||
| Operating cash flow | $95.98M | $22.80M | $9.80M | $11.82M | $40.91M | $8.92M | -$11.26M | $50.74M |
| Capital expenditure | $10.25M | $12.31M | $14.85M | $17.21M | $15.16M | $20.15M | $28.92M | $29.60M |
| Free cash flow | $85.73M | $10.49M | -$5.04M | -$5.40M | $25.75M | -$11.23M | -$40.18M | $21.14M |
| Investing cash flow | -$10.25M | -$43.28M | -$14.85M | -$34.91M | -$15.59M | -$21.65M | -$35.92M | -$4.25M |
| Financing cash flow | -$46.29M | -$818,000 | $8.30M | $24.34M | -$10.24M | -$21.14M | $35.38M | -$7.15M |
| Stock-based compensation | $2.90M | $5.84M | $5.17M | $5.84M | $5.58M | $5.29M | $1.87M | $7.15M |
| Share buybacks | $0 | — | — | $0 | $0 | — | — | $2.47M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.